viewSareum Holdings PLC

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

Sareum Holdings Plc (LON:SAR) CEO Tim Mitchell updates Proactive London's Andrew Scott on the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

Sierra is currently using SRA737 in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Sareum's also been investing a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and the other targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

Quick facts: Sareum Holdings PLC

Price: 0.895 GBX

Market: AIM
Market Cap: £29.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read